PFIZER, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.18 USD | +0.09% |
|
+2.00% | +1.18% |
| 07:28pm | Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says | MT |
| Sep. 12 | Health Care Up on Cyclical Bias -- Health Care Roundup | DJ |
Evolution of the Average Target: Pfizer, Inc.
Evolution of the Target Price: Pfizer, Inc.
Changes in Analyst Recommendations: Pfizer, Inc.
d.4MsHzSc6rGyI6vzdIyFEvQgSEaSSbIOvISZWxokLQMk.gYRxphEP9CTrkMSqRnEu0FdGZd76CfGedF9uhd4zA7CFp22hTn_pI-PYpQ~e40a430f02eadfedbd92552e67ebb4fa
More recommendations
| Analyst Opinion | 4m Revision of opinion | Divergence of analysts' opinions | Divergence of Target Price | Ecart obj. / dr | ||
|---|---|---|---|---|---|---|
| +13.97% | ||||||
| +5.54% | ||||||
| +5.83% | ||||||
| +3.66% | ||||||
| +1.18% | ||||||
| +20.63% | ||||||
| +12.71% | ||||||
| +16.78% | ||||||
| +1.06% | ||||||
| -1.62% | ||||||
| Average | +7.97% | |||||
| Weighted average by Cap. | +7.22% |
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
29.16USD
Average target price
33.23USD
Spread / Average Target
+13.97%
High Price Target
45.00USD
Spread / Highest target
+54.32%
Low Price Target
27.00USD
Spread / Lowest Target
-7.41%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BERENBERG | Kerry Holford |
| GOLDMAN SACHS | Chris Shibutani |
| DZ BANK | Elmar Kraus |
| UBS | Trung Huynh |
| JPMORGAN | Chris Schott |
| JEFFERIES | Akash Tewari |
| DA Davidson | |
| Redburn Atlantic | |
| Morgan Stanley | |
| Leerink Partners | |
| BMO Capital | |
| Argus | |
| Guggenheim | |
| TD Cowen | |
| JPMorgan Chase | |
| Redburn | |
| Wells Fargo Securities | |
| Daiwa Securities | |
| Truist Securities | |
| Cantor Fitzgerald | |
| Barclays | |
| Jefferies & Co. | |
| Credit Suisse | |
| SVB Securities LLC | |
| HSBC | |
| Berenberg Bank | |
| BofA Securities | |
| Atlantic Equities | |
| Citigroup | |
| Mizuho Securities | |
| SVB Leerink | |
| Atlantic Securities | |
| Independent Research | |
| RBC | |
| RBC Capital Markets | |
| J.P. Morgan Chase |
Trading Rating
Investor Rating
ESG Refinitiv
C+
- Stock Market
- Equities
- PFE Stock
- Consensus Pfizer, Inc.